Wedbush sees Rocket Pharmaceuticals as significantly undervalued as cardiac gene therapy pipeline advances [Yahoo! Finance]
Rocket Pharmaceuticals, Inc. (RCKT)
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
rocketpharma.com
Company Research
Source: Yahoo! Finance
The broker maintains its 'outperform' rating and $16 price target on shares trading at $4.97 Wedbush Securities has reiterated its bullish stance on Rocket Pharmaceuticals, the rare disease gene therapy company, after its fourth-quarter update confirmed that patient dosing in its pivotal Phase 2 study of RP-A501 for Danon disease will resume in the first half of 2026. Danon disease is a rare and life-threatening inherited condition affecting the heart, muscles and brain, for which no approved gene therapy yet exists. Wedbush analyst Yun Zhong said that with a minimum four-week interval required between dosing of the three additional patients due to receive treatment, all patient dosing could be completed by the third quarter of 2026, potentially allowing the US Food and Drug Administration to complete its data review by year end. The broker also highlighted the expansion of the company's cardiac pipeline, with a third programme, RP-A701 targeting BAG3-dilated cardiomyopathy,
Show less
Read more
Impact Snapshot
Event Time:
RCKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCKT alerts
High impacting Rocket Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RCKT
News
- Rocket Pharmaceuticals (RCKT) had its price target raised by The Goldman Sachs Group, Inc. from $2.00 to $3.00. They now have a "sell" rating on the stock.MarketBeat
- Rocket Pharmaceuticals (RCKT) was upgraded by Lifesci Capital to "strong-buy".MarketBeat
- RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals (RCKT) had its price target raised by Cantor Fitzgerald from $8.00 to $10.00. They now have an "overweight" rating on the stock.MarketBeat
- Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress [Yahoo! Finance]Yahoo! Finance
RCKT
Earnings
- 2/26/26 - Beat
RCKT
Sec Filings
- 3/2/26 - Form S-3
- 2/26/26 - Form 8-K
- 2/26/26 - Form 10-K
- RCKT's page on the SEC website